Physician profile
Brooke N Dees
NPI 1912469156
$4,295.06
in general payments reported to CMS, 2019-2025
26 companies · $823 in 2025
The $823 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,245 · 2022: $799 · 2023: $751 · 2024: $677 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $808.80 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $536.25 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $457.71 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $402.23 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.09 | 2021-2025 | Jardiance |
| Pfizer INC. | $296.08 | 2021-2025 | |
| Amgen INC. | $239.61 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $219.01 | 2025 | Pascal |
| Lexicon Pharmaceuticals, INC. | $211.96 | 2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.90 | 2021-2025 | Lifevest |
| Baxter Healthcare | $104.58 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $100.02 | 2021-2022 | |
| Amarin Pharma, INC. | $69.26 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.87 | 2021-2023 | Farxiga |
| Esperion Therapeutics, INC. | $58.36 | 2021-2023 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.21 | 2021-2025 | |
| Abiomed | $41.27 | 2025 | |
| Shockwave Medical, INC | $25.91 | 2021 | |
| Atricure, INC. | $21.45 | 2023 | |
| Impulse Dynamics (USA) INC. | $20.91 | 2023 | Optimizer |
| Chiesi USA, INC. | $20.67 | 2024 | Kengreal, Cleviprex |
| Scpharmaceuticals INC. | $20.38 | 2025 | |
| Abbott Laboratories | $20.15 | 2024 | Diamondback Coronary |
| Boston Scientific Corporation | $16.83 | 2022 | |
| Novo Nordisk INC | $16.01 | 2023 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Dees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.